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Focus on Professor Leslie Meltzer Henry . . .
Tireless Advocate for the Ethical Conduct of 
Medical Research
Essential Medicines symposium speakers (from l to r) Prof. Peter Danchin, 
Ambassador Necton D. Mhura, Prof. Diane Hoffmann and Prof. Leslie Meltzer Henry
On October 29-30, 2015, Law & Health Care Professor Leslie Meltzer 
Henry, along with colleagues Diane Hoffmann and Peter Danchin, Director 
of the Maryland Carey Law's International and Comparative Law Program, 
organized a unique symposium that brought together legal academics, IRB 
members, and medical researchers from North America and southern Africa 
for an “International Symposium on Clinical Trials and Access to Essential 
Medicines in African Countries.”  The symposium, co-sponsored by the 
Faculty of Law at Chancellor College in Malawi, examined ethical and legal 
challenges to developing and distributing essential medicines for diseases 
such as HIV and malaria in African countries.
The symposium was the latest in a long collaboration between Maryland 
Carey Law and the Faculty of Law at Chancellor College in Malawi which 
began in 2010 when University of Maryland, Baltimore’s (UMB) Center 
for Global Education Initiatives sent an interprofessional team of faculty 
and students to Malawi to study the health and legal needs of orphans and 
vulnerable children.  The Honorable Necton D. Mhura, Ambassador from 
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Malawi to the United States, opened the roundtable by recounting the 
history of the collaboration.  In the summer of 2013, Hoffmann and 
Danchin traveled to Malawi and worked with Malawian law professor 
Chikosa Banda to organize a workshop for students and faculty from 
both universities on the subject of HIV/AIDS. Since that time, faculty 
members from both schools have conducted visits and workshops in both 
Baltimore and Malawi.
Professor Henry was brought into the Essential Medicines symposium 
because of her expertise and her extensive scholarship on clinical 
research ethics.  Based on her work in this area, she is frequently asked to 
provide expert commentary for federal and local agencies, organizations, 
and the media on ethical issues that arise in human subjects research.  
She has also served as a bioethics consultant for the Department of 
Defense and has presented to panels of experts at the Department of 
Health and Human Services, the Food and Drug Administration (FDA), 
and the National Institutes of Health Bioethics Advisory Committee.  
Professor Henry is also a core faculty member at the Johns Hopkins 
Berman Institute of Bioethics.  Her recent scholarship in this area ranges 
from compensation for research subjects who sustain research-related 
injuries and commentary on changes to the Common Rule.  She also 
teaches both the survey and advanced bioethics courses at the law school.
Selected Articles by Professor Leslie Meltzer Henry 
• Respect and Dignity: A Conceptual Model for Patients in the 
Intensive Care Unit, 5.1A Narrative Inquiry in Bioethics 5A 
(2015) (with C. Rushton, M.C. Beach, and R. Faden). 
• Just Compensation: A No-Fault Proposal for Research-Related 
Injuries, Journal of Law & the Biosciences (2015). 
•	Moral Gridlock: Conceptual Barriers to No-Fault Compensation 
for Injured Research Subjects, 41 Journal of Law, Medicine & 
Ethics 411 (2013). 
•	Revising the Common Rule: Prospects and Challenges, 41 
Journal of Law, Medicine & Ethics 386 (2013).
Henry’s interest in international human subjects research is largely 
focused on what researchers from the United States owe host countries 
and research subjects in those countries based on the International 
Ethical Guidelines for Biomedical Research Involving Human Subjects 
published by the Council for International Organizations of Medical 
Sciences (CIOMS).  The guidelines, published in 2002, provide guidance 
on the ethical justification and scientific validity of research, ethical 
review of research, and informed consent, among other topics.  Her 
expertise in this area added greatly to the conference planning.
The four collaborators – Henry, Hoffmann, Danchin and Banda – 
organized the conference around four panels:
1) Access to Essential Medicines as a Human Right;
2) The Law and Ethics of Clinical Trials: What Rules Should 
Govern Clinical Research in Africa;
3) What do Clinical Researchers and Sponsors Owe to Host 
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Communities?;
4) Legal Regimes and Obstacles: Free Trade, 
Intellectual Property, and Access to Medicine.
Each panel was composed of an interprofessional 
and international group of speakers who shared their 
academic and personal perspectives of conducting 
research in southern Africa where such research brings 
both enormous promise and the potential for grave 
ethical conflicts. 
Professor Henry moderated the third panel on 
the responsibilities of clinical researchers to host 
communities.  Research conducted in lower income 
countries often involves ethical issues that are more 
complex than in developed countries because of 
power differentials, lack of health care outside of 
clinical trials, and the potential for exploitation of 
research subjects.  Professor Henry’s panel discussed 
several frameworks that aim to create more equitable 
interactions between researchers and participants and 
host communities.  Joining her on the panel were Dr. 
Joseph Mfutso-Bengo, Professor of Bioethics and 
Director of the Centre for Bioethics at the University 
of Malawi College of Medicine and Dr. David 
Wendler, Head of the Section on Research Ethics in 
the Department of Bioethics at the National Institutes 
of Health.  Both Dr. Mfutso-Bengo and Dr. Wendler 
have written extensively on these topics and brought 
perspectives from both sides of the Atlantic.
The first issue tackled by Professor Henry’s panel 
related to the interpretation of the requirement to 
provide “reasonable availability” of any product 
developed during the trial to the host country/
research population.  The idea of making interventions 
reasonably available emerged in 1993 from guidelines 
issued by CIOMS (and later strengthened in 2002).  
The guidelines stress that the sponsoring agency 
conducting the research should make any product 
developed through the research “reasonably available” 
to the community in which the research is conducted.  
How these guidelines should be interpreted – 
including such issues as who should make the 
decision as to what is reasonable and what constitutes 
“available” – was tackled by the panelists and others.
Professor Henry’s panel members also discussed the 
issues of ancillary care obligations, or obligations to 
provide care to research participants that is not related 
to the research question, and the provision of “fair 
benefits,” another ethical framework for research.
The fair benefits framework requires that research 
be conducted in developing countries only if three 
conditions are met:  1) the research addresses a health 
problem of the developing country population, 2) the 
research objectives provide a strong justification for 
conducting the research in the chosen community, and 
3) the research poses few risks to the participants or 
the benefits to them clearly outweigh the risks.
Chikosa Banda, Professor, Faculty of Law at 
Chancellor College in Malawi
Mark Barnes, Partner, Ropes & Gray, LLP
Danwood Chirwa, Professor, University of Cape 
Town Law Faculty 
Peter Danchin, Professor and Director of the 
International and Comparative Law Program, 
University of Maryland Carey School of Law
Sean Flynn, Associate Director, Program on 
Information Justice and Intellectual property, 
American University Washington College of Law 
Lisa Forman, Assistant Professor, University of 
Toronto 
Diane Hoffmann, Professor and Director of 
the Law & Health Care Program, University of 
Maryland Carey School of Law
Heinz Klug, Professor and Director, Global Legal 
Studies Center, University of Wisconsin
Miriam Laufer, Associate Professor, University 
of Maryland School of Medicine 
Joseph Mfutso-Bengo, Professor of Bioethics and 
Director of the Centre for Bioethics, University of 
Malawi College of Medicine
The Honorable Necton D. Mhura, Malawian 
Ambassador to the United States
Victor Mwapasa, Associate Professor, University 
of Malawi College of Medicine 
Seema Shah, Faculty Bioethicist, NIH* 
Hilda Kaluwa Soko, Law Lecturer, University of 
Malawi Chancellor College of Law 
David Wendler, Senior Investigator and Head of 
the Section on Research Ethics, NIH 
Lucie White, Professor, Harvard Law School
*Ms. Shah was unable to attend the conference, but her 
remarks were given by David Wendler
The symposium was supported by the UMB Center for 
Global Education Initiatives, Alan & Nancy Eason, the 
Stuart Rome Lecture Fund, the Reuben Shiling Mental 
Health Law Fund, the Leonard C. Homer/Ober|Kaler 
Law and Health Care Fund, and the Dr. Richard H. 
Heller Fund.
Conference Speakers, Moderators  
& Supporters
Cont. on page 4
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Other Collaborations
In addition to organizing the Essential Medicines 
symposium this year, Professor Henry has been 
working intensively as a co-investigator on two 
projects relating to the ethical conduct of medical 
research.  The first project is an NIH-funded, multi-
year project called PHASES (Pregnancy & HIV/
AIDS: Seeking Equitable Study), which is designed 
to establish ethically and legally acceptable strategies 
for conducting research about HIV treatment and 
prevention during pregnancy.  Henry’s collaborators 
include Ruth Faden at the Johns Hopkins Berman 
Institute of Bioethics, Maggie Little at Georgetown’s 
Kennedy Institute of Ethics, Annie Lyerly at the 
University of North Carolina, and Anna Mastroianni at 
the University of Washington School of Law. 
The project was created to address a gap in the 
diagnosis and treatment needs of pregnant women, a 
key population affected by HIV/AIDS.  In November 
2014, the PHASES team met with former FDA 
regulators, pharmaceutical company representatives, 
IRB chairs, and legal academics to begin the process 
of creating an ethical framework that would permit 
research with pregnant women with HIV.  Research 
under the PHASES grant has been conducted in the 
United States to date, but the research team recently 
received four more years of funding to continue their 
research in South Africa, Botswana and Malawi.  The 
PHASES team is currently conducting engagement 
meetings at these sites with community members, 
local investigators, and local IRBs. 
Henry and her PHASES collaborators also 
were recently funded by the Wellcome Trust to 
develop ethical and legal guidance for conducting 
research with pregnant women during public health 
emergencies, like the Zika crisis, where there is 
an urgent need to attend to the health needs of 
pregnant women and their offspring.  The project is 
called “Conducting Ethical Research with Pregnant 
Women in the Emerging Zika Pandemic and Beyond: 
Challenges Arising in Public Health Crises.” The goals 
of the project are to engage key experts in order to 
understand the needs and challenges of conducting 
research on women whose pregnancy may be affected 
by Zika and to develop a framework to conduct 
research with this population.  The project will include 
working with medical researchers to determine when 
research requires participation of pregnant women and 
what the barriers are to conducting such research in 
certain target countries.  Ultimately the team hopes to 
create guidance documents intended to be of real-time 
utility in the Zika crisis and future public health crises. 
Professor Ellen Weber: Front and Center on Protection 
of Individuals with Mental Health and  
Substance Use Disorders
The Drug Policy Clinic at University of Maryland 
Carey Law is working to address Maryland’s heroin 
and prescription drug problem by helping individuals 
gain access to health insurance coverage and tackling 
systemic barriers to drug treatment.  The Clinic 
was created by Professor Ellen Weber to address 
practices that inhibit the expansion of drug treatment 
in communities and the criminal justice system and 
that discriminate against individuals with histories 
of drug dependence.  To identify the most pressing 
client issues, the Clinic established medical-legal 
partnerships (MLPs) at two Baltimore drug treatment 
programs – Man Alive and Institutes for Behavior 
Professor Ellen Weber
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Resources in August 2015.  Both programs provide 
methadone maintenance treatment and outpatient 
counseling services to hundreds of patients with 
substance use disorders, and offer “health homes” for 
patients with Medicaid who have multiple chronic 
health issues.  Two student teams from the clinic 
assisted patients with problems obtaining Medicaid or 
private insurance coverage and accessing health care.  
They also looked for system-wide standards that could 
be the source of client problems.  Weber described the 
value of this type of advocacy clinic to law students 
- “the collaboration has exposed our students to the 
complex financing system for drug treatment, and they 
have learned to help patients navigate multiple public 
and private health insurance programs.”  
Both teams quickly learned that patients with 
Medicare coverage face significant barriers accessing 
drug treatment, particularly methadone maintenance 
treatment. The teams launched several projects to 
assist patients, including identifying those who were 
eligible for programs that reduce the cost of Medicare 
premiums and prescription drugs.  Student-attorneys 
Brenda Kathurima and James Cook also conducted 
training programs about Medicare coverage to help 
program administrators assist patients and to educate 
policymakers about the need to secure stable funding 
for the growing population of patients with Medicare 
coverage. 
Man Alive identified a group of patients who 
should have been able to use their private secondary 
insurance policy – often a retiree policy – to cover 
their drug treatment, but faced administrative 
barriers imposed by both the Center for Medicare 
and Medicaid Services (CMS) and private carriers. 
Student-attorneys Isabel Coello and Mike Martin 
worked with the clients and the program’s clinical and 
administrative staff to document treatment and claims 
histories and then make the case to insurance carriers 
that the private policies should pay outstanding and 
future claims. The team’s efforts have resulted in 
positive outcomes for each client. The carriers have 
reimbursed over $4300 in unpaid claims, some dating 
back many months, and are now paying all claims 
without delay. The team has also developed a toolkit 
that will help treatment programs around the state 
address these reimbursement issues for their patients.  
The Clinic has also helped individuals with private 
insurance challenge discriminatory reimbursement 
decisions and advocate for better enforcement of 
the federal Mental Health Parity and Addiction 
Equity Act. One hospital-based treatment program 
discovered that a national insurance carrier had 
repeatedly denied reimbursement for methadone 
treatment services for patients with both individual 
and small employer plans sold on the State’s health 
benefit exchange. Student-attorney Kris Corwin has 
represented one patient whose plan denied coverage 
for methadone treatment in violation of state law.  In 
the course of his investigation, Kris identified plan 
standards that impose more restrictive utilization 
review requirements for substance use and mental 
health treatment than for medical services.  The 
Clinic reported these potential Parity Act violations 
to the Maryland Insurance Administration, which has 
launched an investigation of the carrier’s practices.  
In the meantime, the carrier admitted, in response to 
the Clinic’s insurance appeal, that it had incorrectly 
denied coverage for the client’s methadone treatment. 
The carrier reimbursed the methadone clinic $2700 for 
the client’s care.  
The Drug Policy Clinic has also identified Parity 
Act violations in the Maryland Medical Assistance 
program and has looked to the Maryland General 
Assembly to require compliance.  Beginning in 
September 2014, the Clinic and its partners began to 
work with the State’s Medicaid officials to develop 
a comprehensive substance use disorder benefit that 
complied with the Parity Act. When discussions failed 
to resolve outstanding benefit problems, the Clinic 
drafted legislation (HB 1217/SB 899), introduced 
in the 2016 legislative session, to require the State 
to bring its Medicaid benefit into compliance with 
federal law.  The Clinic and its partners advocated 
successfully with members of the General Assembly, 
resulting in overwhelming support and passage of the 
bills. The State is required to adopt regulations by 
July 1, 2017 and those standards should result in more 
comprehensive services for the State’s most vulnerable 
youth and adults.   
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Professor Karen Rothenberg Creates Unique 
NIH Field Placement for Health Law Students
In Fall 2015, Law & Health Care Program faculty 
member and former Dean of the law school, Karen 
Rothenberg, created an opportunity for four students 
to work and study at the National Institutes of Health 
(NIH) through a new externship program that, based 
on its positive response, she will lead again in Fall 
2016.  Rothenberg, a national expert in the ethical, 
legal and social implications of genetic testing and 
genomic research, developed the externships with 
colleagues at NIH whom she met during her four 
years as Senior Advisor to the Director of Genomics 
& Society at the National Human Genome Research 
Institute (NHGRI).  Rothenberg is now back at 
Maryland Carey Law and continues to serve as a 
Visiting Scholar in the Department of Bioethics at 
NIH’s Clinical Center.  According to Rothenberg, the 
externship program “provides a unique opportunity for 
law students to experience the making of health policy 
at the most prestigious medical research institution 
in the world while having opportunities to delve into 
cutting edge research topics at the intersection of 
ethics, law, and science.  In addition to working with 
world renowned health policy makers, the students 
had the opportunity to round in the Clinical Center 
and meet the patients who hope to benefit from the 
advances in genomics research.”
The four students were placed in different 
offices in NIH and NHGRI: the Technology 
Transfer Office, the Division of Genomics and 
Society, the Department of Bioethics at the NIH 
Clinical Center, and the Social and Behavioral 
Research Branch with the Senior Advisor for 
Genomics and Health Disparities.  Their diverse 
research projects included the ethical and legal 
implications of the use of legacy samples, gene 
editing, the Precision Medicine Initiative, and 
health disparities in access to designer drugs.  
The students spent two days a week at NIH in 
Bethesda, Maryland attending Undiagnosed 
Diseases Program rounds and NHGRI 
Institutional Review Board (IRB) meetings, 
conducting research and writing memos for 
their supervisors and developing an extensive 
written research project.  
The four students divided their time between 
working with their NHGRI supervisors and 
participating in the accompanying workshop with 
Professor Rothenberg.  The purpose of the split 
structure was to introduce students to the day-to-
day work of NIH lawyers, to provide a structured 
opportunity for students to share their experiences, and 
to allow students to explore more deeply the ethical, 
legal, social and policy challenges raised by genomics 
research.  The students were also required to keep 
a weekly journal reflecting on their participation in 
clinical rounds, their weekly assignments with their 
supervisors, and research related to research projects. 
Apurva Dharia (3L), who was placed in the 
NHGRI Technology Transfer Office, reflected on the 
experience, “I was able to work closely with and learn 
from the licensing and technology transfer specialists 
within the National Human Genome Research 
Institute. As part of my experience I was able to draft 
licensing and transfer agreements, catalogue NIH 
patent portfolios, and research important bioethics 
and intellectual property issues related to the cutting 
edge of genomics research. As part of an incredibly 
enlightening externship and workshop we were 
privileged to learn from the Nation's foremost experts 
in bioethics in genomics research.”
Dr. Eric Green, Director, NHGRI Speaks to Professor Rothenberg’s  
Externship Students
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Law & Health Care Program Celebrates 30th Anniversary 
with “Health Law: Past, Present, and Future” Panels
On October 30, 2015, the Law & Health Care 
Program celebrated its 30th anniversary with a panel 
discussion on “Health Law: Past, Present, and Future” 
followed by a gala celebration in the law school’s 
historic Westminster Hall.  The panel discussion gave 
120 program alumni and local health law practitioners 
the chance to hear from experts in different areas of 
health law about how health law has changed over the 
years from a loosely to a highly regulated industry, 
where we are now with the Affordable Care Act 
(ACA), and the way in which biotechnology and big 
data promise to transform the health care industry 
– and the field of health law – in the future.  At the 
reception and celebration, attendees listened to a 
staged reading of a bioethics play written by Professor 
Karen Rothenberg and a song written by adjunct 
Professor Jaime Doherty and his law partner Jeff 
Pecore that revealed the more lighthearted side of the 
L&HCP.
The “Health Law: Past, Present, and Future” event 
started with a look back at how health law was studied 
and practiced a generation ago.  The panelists who 
spoke about “Health Law: Past” were Joanne Pollak 
’76, Senior Vice President and General Counsel at 
Johns Hopkins Medicine, Sanford "Sandy" Teplitzky,  
Principal at Ober|Kaler, and Jack Schwartz, Adjunct 
Professor and former Maryland Assistant Attorney 
General and Director of Health Policy Development 
at the Maryland Office of the Attorney General.  With 
questions from L&HCP Professor Leslie Meltzer 
Henry, all three panelists agreed that they “stumbled” 
into the practice of health law largely because it was 
not an established field of study or practice when 
they started their legal careers.  Courses in Law & 
Psychiatry or Forensic Medicine existed, but beyond 
these meager offerings, the panelists described their 
providential entrance into health law by accepting law 
firm and governmental positions in which they were 
tasked with some aspect of regulation of the health 
care industry.  
Pollak described learning about the regulation of 
the health care industry as a young lawyer at Piper 
& Marbury (now DLA Piper) when three important 
pieces of legislation were passed in Maryland– the 
Maryland Certificate of Need Law (1969), the 
law establishing the Maryland Health and Higher 
Educational Facilities Authority (1970) and the Health 
Services Cost Review Commission law (1971).  
These early regulatory laws trained Pollak in the 
complexities of the health care industry which have 
formed the basis of her career largely as counsel for 
Johns Hopkins Medicine.  
Working on complex end-of-life care cases that 
arose in the 1970s when he worked at the Maryland 
Sanford Teplitzky, Joanne Pollak (’76), Adjunct Prof. Jack Schwartz and Prof. Leslie Meltzer Henry (from l to r) 
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Office of the Attorney General set the stage for 
Schwartz’s career as an expert in law and bioethics, 
particularly end of life care and the right of patients to 
refuse life sustaining treatment.  Teplitzky and Pollak 
also described their work on early informed consent 
cases.  Pollak recalled arguing a case at the bedside of 
a patient who did not consent to life saving treatment.  
Pollak argued – and the judge agreed – that the 1977 
Sard v. Hardy case (379 A.2d 1014) that established 
the standard for informed consent in Maryland also 
provided patients with the option not to consent 
to medical treatment.  The panel agreed that these 
informed consent cases and Jehovah’s Witnesses cases 
during the same time period fundamentally changed 
patients’ relationships with their doctors.  Finally, 
Teplitzky talked about the evolution of the nation’s 
body of fraud and abuse laws that also grew up in the 
last thirty years.  His early work at the US Department 
of Health and Human Services in the office that 
supported the Medicare program led to a long career 
developing and interpreting fraud and abuse laws, 
which he now does at the law firm of Ober/Kaler. 
The second panel was moderated by L&HCP 
Professor Ellen Weber and focused on current issues in 
health law through a Maryland lens.  Panelists Carolyn 
Quattrocki, Executive Director of the Maryland Health 
Benefit Exchange, and Peter Parvis ’77, a Partner at 
Miles & Stockbridge, focused on recent changes to 
Maryland’s unique Medicare waiver and Affordable 
Care Act implementation in Maryland.
Under Maryland's “old” waiver which came into 
place in the mid-1970s, Parvis explained, Maryland 
hospitals received a waiver from federal Medicare 
payment methods (i.e., diagnostic related groups) if 
all payers were charged the same rate for services and 
the cumulative growth in Maryland inpatient payments 
was less than the growth of US government inpatient 
payments.  This system was designed to ensure that 
uninsured patients were not charged the full amount 
for medical services but rather charged the negotiated 
rates paid by insurance companies.  It also kept rates 
reasonably related to costs which, for many years, 
led to the lowest “markup” in the country for medical 
services.  Parvis explained that Maryland has moved 
to a new waiver program that started January 1, 2014 
as a five-year demonstration project.  Under this new 
“global budgeting” waiver program, each Maryland 
hospital’s total annual revenue and reimbursement 
amount will be known at the beginning of the fiscal 
year based on historic data adjusted to account for 
inflation.  The program limits the annual increase 
in total per capita hospital costs in Maryland to less 
than 3.58%.  This program is designed to focus on 
population health, prevention, and cost savings by 
including measures that reduce readmissions, avoid 
preventable hospitalizations and complications, and 
increase wellness programs.  
Ms. Quattrocki described the “big decisions” that 
shaped Maryland’s implementation of the ACA.  As 
soon as the law was passed, Maryland’s Governor set 
up a task force that determined that the state should 
be a national leader in ACA implementation, expand 
Medicaid, and create a robust quasi-public health 
insurance exchange.  Despite early computer problems 
that stalled the roll out of the exchange, as of October 
2015, the reforms brought 750,000 people into either 
private insurance or Medicaid and decreased the 
percentage of uninsured from 10.9% of the population 
to approximately 4.9%.
Finally, the attendees were galvanized by the 
discussions of the “Future” panel.  Speaking on the 
panel were L&HCP faculty members Frank Pasquale 
and Amanda Pustilnik, as well as prominent alumni 
David Cade ’85, CEO of the American Health 
Lawyers Association, and Marcus Wang ’08, Co-
Founder of ZytoGen, LLC, a preimplantation genetic 
diagnosis company.  Professor Diane Hoffmann, 
who moderated the panel, started off by asking 
Cade to comment on the biggest issues that would 
face health lawyers in the next decade.  Looking 
toward the future, Cade noted that the health law 
issues that are likely to grow in prominence are 
regulation of privacy and data security, big data 
and data analytics, and digital technology such as 
mobile medical applications.  Professor Pasquale, a 
Prof. Amanda Pustilnik, David Cade (’85), Marcus Wang ('08) 
and Prof. Frank Pasquale (from l to r) 
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nationally-recognized big data expert, followed up 
on this point and urged the gathered health lawyers to 
defend professional autonomy from being overtaken 
by technology.  He explained the risk that predictive 
analytics and pattern recognition may lead people to 
conclude that professional judgement is not necessary 
for physicians to diagnose and treat illness. The 
automation of disability determinations would also 
challenge fundamental rights to due process and 
undermine claimants’ dignity. Based on his research 
on big data, predictive analytics, and artificial 
intelligence in fields where these technologies are 
more advanced, Pasquale believes lawyers need to be 
involved in their deployment in health care settings, 
to assure they are accurate, ethically sound, and 
economically fair across socioeconomic groups.
Professor Pustilnik, an expert in the intersection of 
the law and neuroscience, spoke about technology as 
a new frontier for lawyers that will require all of us 
to understand the law in new ways and to question if 
current law is adequate to address the legal and ethical 
issues that new technologies bring.  Pustilnik focused 
on the use of neuroscience tools to diagnose and 
understand pain.  Historically no tools have existed to 
measure pain and when the cause of pain is not clear 
physicians and legal bodies do not know how to assess 
it.  The experience of pain has legal ramifications in 
terms of disability compensation, determination of 
tort damages, and health insurance benefits (among 
other things) but it is often poorly understood by the 
judicial and administrative bodies that encounter it.  
Misunderstanding of pain is particularly common 
when it is unrelated to an injury or separate disease 
state.  Chronic pain that is not peripheral to another 
condition is often typically treated as a psychiatric 
disorder although neuroscience technologies are now 
able to demonstrate that chronic pain causes – and is 
caused by – changes in brain function.  Pustilnik hopes 
to see pain considered a neurological disease from 
a medical, legal, and policy perspective.  Pustilnik 
was recently invited to join a working group of the 
International Association for the Study of Pain to 
develop international standards for the legal uses of 
brain imaging.  
Finally, Marcus Wang focused his comments on 
the promises and potential ethical complications of 
reproductive technologies.  Although he sees the clear 
benefit of providing parents the opportunity to select 
healthy embryos for implantation, he is aware that the 
ability to control which embryo becomes a child raises 
Prof. Karen Rothenberg, L&HCP Director Diane Hoffmann 
and L&HCP Managing Director Virginia Rowthorn  
(from l to r)
Adjunct Professor Jamie Doherty and Jeff Pecore
challenging ethical issues especially at the macro level 
where overuse of the technology could lead to gender 
imbalance and elimination of certain conditions and 
disabilities.  
The give-and-take between panelists and audience 
highlighted the tension between the great promise of 
technology, its attendant ethical and legal dilemmas, 
as well as the clear role of lawyers to help ensure that 
an appropriate and just balance is reached between the 
two. 
The evening – with its scholarly conversations and 
celebratory moments – was a reflection of the dream 
that Professor Karen Rothenberg had when she started 
the L&HCP in 1983. Four years later, Diane Hoffmann 
left a practice at Dewey Ballantine to help forge 
new ties with the health sciences on the University 
of Maryland, Baltimore campus.  By 1988, the law 
school had 11 courses in everything from Civil Rights 
of Individuals with Disabilities to Legal and Ethical 
Issues in Biotechnology. The program now boasts 11 
faculty members and has graduated over 400 students 
with the Certificate in Health Law.
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Health Law Students Partner with Mississippi Center for 
Justice during Annual Service Trip
by: Reena Palanivel and Allison Best  
(2016 Trip Leaders)
Maryland Carey Law students have been traveling 
since early 2006 to the Gulf region of the United 
States to help with the vast need for legal services 
created by Hurricane Katrina.  In 2009, the Law 
& Health Care Program (L&HCP) approached the 
Mississippi Center for Justice (MCJ) in Jackson about 
creating a trip that focused on health law.  MCJ has 
a well-established health law practice in Jackson and 
in the northern Delta region of Mississippi focused 
primarily on access to health care and the legal needs 
of individuals with HIV disease.  Since 2010, groups 
of 10-12 health law students have spent a week in 
Mississippi during winter break working closely with 
MCJ attorneys on outreach and advocacy efforts.
On this year’s annual Health Law trip, Maryland 
Carey Law students had the opportunity to work on 
several projects focused on HIV/AIDS advocacy and 
the Affordable Care Act in the Jackson, Mississippi 
region. To kick off the week, the group of twelve 
health law students visited a transitional group home 
for individuals living with HIV/AIDS in inner city 
Jackson. The residents of the home shared stories of 
the biggest challenges they have faced since learning 
of their diagnosis. In response to questions on a legal 
needs screening tool administered by the students, 
the residents identified the areas of the law that still 
need the most improvement. Every resident agreed 
that ending the stigma surrounding HIV/AIDS is the 
most important step to ensuring individuals can live 
well with HIV/AIDS and in ending the epidemic, 
altogether.
In addition to visiting the group home, half of the 
health law students worked on research projects 
focused directly on the prevalence and impact of HIV/
AIDS on different groups around Mississippi. One 
project focused on exploring how HIV/AIDS impacts 
the Latino population in Mississippi, many of whom 
are undocumented and do not have consistent access 
to health care. Another group compared HIV/AIDS 
statistics between Mississippi and Arkansas in order 
to identify which outreach strategies and programs 
have had the best outcomes on improving access to 
HIV/AIDS testing and medical care. The third group 
researched medical-legal partnerships that work with 
community health centers to improve access to care. 
The Mississippi Center for Justice plans to use all of 
the data and information collected by the Maryland 
Carey Law health law students to prepare its agenda 
for the coming year and adjust its focus to cover the 
unmet legal needs of low-income Mississippians. 
The second project required legal research, 
data collection, and brainstorming ideas on the 
implementation of the Affordable Care Act.  The deep 
south is an area in the country that has high poverty 
rates which correlates with a high number of uninsured 
individuals.  Some of the major issues involve lack of 
understanding of the Affordable Care Act, awareness 
of the state’s provisions and benefits, and services for 
health care.  For this project, the students compiled 
data regarding the uninsured rates in the state of 
Mississippi and observed the correlation between 
different federal poverty levels.  They also researched 
the Medicaid enrollment centers in the Delta, mapped 
out the eighty-four centers and discovered the very 
Mississippi Center for Justice team and MD Carey Law Health Law students discuss research projects 
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limited days and times per month that individuals can 
visit them.  Lastly, the students identified outreach 
and education organizations that the MCJ could team 
up with in order to teach families how to enroll their 
children into the Children's Health Insurance Program 
(CHIP).  The research project will help the Mississippi 
Center for Justice focus on outreach and advocacy to 
increase the number of insured individuals in the state.
Throughout the week, the Maryland Carey Law 
students enjoyed experiencing Mississippi’s culture.  
The students were able to explore not only the city 
of Jackson, but also the more rural Delta area.  They 
On January 13, 2016, the Maryland/DC Society for Healthcare Risk 
Management and the Maryland Bar Association co-sponsored a conference at 
the law school titled “When Worlds Collide:  The Intersection of Healthcare, 
Law & Technology.”  Director of the L&HCP Diane Hoffmann helped 
organize the event which was developed with two themes in mind – the 
demonstrations related to the death of Freddie Gray and the role of social 
media and technology in health care.  The symposium was attended by over 
200 local risk managers and focused on four topics: the Public Behavioral 
Health Crisis; Medical and Policy Implications of Mental and Behavioral 
Health; Social Media and Privacy in Healthcare; and Anticipating Patient 
and Legal Risks Associated with Emerging Technology.  The first two 
panels focused on heightening awareness of the specific issues faced by law 
enforcement officers when responding to individuals who are experiencing 
a behavioral or emotional health crisis.  These challenges in the field are then exacerbated by the lack of 
behavioral health resources and the lack of acute care beds and outpatient services for the behavioral health 
patient populations.  The second two panels brought together risk managers, hospital attorneys and legal 
academics to discuss the unique challenges that technology brings to the provision of health care.  
Professor Hoffmann moderated the Social Media and Privacy in Healthcare panel which included L&HCP 
Professor Frank Pasquale, a national expert in social media and health care privacy.   Pasquale has an active 
Twitter presence with 11,700 followers at @FrankPasquale and is a contributing member of the Concurring 
Opinions blog which focuses on a broad range of legal topics including big data and social media issues.  The 
panel looked at access by the media to information about a breaking story or newsworthy event involving 
an individual who becomes a patient at the hospital and how the hospital can get better control over the 
social media that is put out about such individuals or the hospital more generally.  The panelists – a former 
television producer who now works in communications at a university, a hospital attorney and Pasquale – 
looked at the issue from their professional perspectives.  Tim Parsons, now Director of Communications 
at Johns Hopkins Carey School of Business, spoke about his experience trying to get news from hospitals 
as a television producer and also, in his current role, acting as a gatekeeper of information from the 
media.  Pamela Rayne, Associate Senior Counsel at Johns Hopkins Health System, spoke about navigating 
between the needs of the media and the legal needs of the hospitals and patients.  Professor Pasquale 
discussed the kinds of things that have gotten on to social media that perhaps should not have and he related 
some problematic legal cases and news stories in which health care providers shared patient images or 
information on social media. Finally Pasquale suggested some policies that health care providers might 
want to think about for employees/staff as to their use of social media.
Professor Frank Pasquale
Professors Pasquale and Hoffmann Focus on  
Social Media and Risk Management
toured the Mississippi State Capitol and had the 
opportunity to meet with several congressmen.  They 
met representatives of different health organizations 
and collaborated on ideas on how to improve the 
health system in the state.  Finally, they ate delicious 
southern comfort food, listened to jazz music, and 
toured the BB King Museum.  The Health Law trip 
provided the Maryland Carey Law students with an 
amazing, first-hand opportunity to learn about critical 
issues in health law in a rural setting very different 
from their home in Baltimore. 
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This year, in December and again in May, Diane 
Hoffmann, Director of the Law & Health Care 
Program (L&HCP) and her University of Maryland 
Baltimore (UMB) co-investigators held meetings 
supported by their NIH-funded grant, “Microbiota 
Transplantation: Recommendations for a Regulatory 
Framework.”  As we reported in a prior newsletter, 
in June 2015, the UMB team was awarded a grant 
from the National Institute for Allergy and Infectious 
Diseases (NIAID) to study the legal and regulatory 
aspects of a cutting edge medical treatment called 
microbiota transplantation (MT).  MT is the 
transplantation of communities of microorganisms 
from one individual to another.  The two-year grant 
is facilitating a project to study regulatory options for 
fecal microbiota transplantation and other emerging 
MT options including vaginal, skin, anterior nares, 
oral, and whole body microbiome transplants.
At present, there is much interest and increasing 
evidence-based support for one type of MT - fecal 
Hoffmann and Co-Investigators Bring Together 
Working Group to Discuss Regulation of  
Microbiota Transplantation
microbiota transplantation (FMT) - which involves 
the transplantation of fecal material obtained from a 
healthy individual into the gastrointestinal tract of a 
patient recipient to treat disease.  FMT has been found 
particularly effective in treating recurrent Clostridium 
difficile	infection	(CDI), a virulent infection that 
causes inflammation of the colon and deadly diarrhea.  
According to the CDC, CDI causes almost half a 
million infections among patients in the United States 
every year.  In 2011, approximately 29,000 patients 
died within 30 days of the initial diagnosis of CDI 
and of those, about 15,000 deaths were estimated 
to be directly attributable to CDI putting it among 
one of the top causes of infectious disease death in 
the United States.  It is the most common microbial 
cause of healthcare-associated infections in US 
hospitals and costs up to $4.8 billion each year in 
excess health care costs for acute care facilities alone.  
More than 80 percent of the deaths associated with 
CDI occurred among Americans aged 65 years or 
Microbiota Transplantation Co-Investigators after May meeting
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older.  Importantly, one out of every five patients with 
healthcare-associated CDI experience a recurrence of 
the infection.  
FMT is used to treat patients with recurrent CDI 
who, in the past, had few treatment options.  Before 
FMT was clinically available – and still to this day – 
desperate patients have resorted to “do-it-yourself” 
FMT at home in some cases relying on YouTube 
videos that provide detailed instructions.  According 
to Catherine Duff, Executive Director of The Fecal 
Transplant Foundation, a nonprofit that is advocating 
for safer, more widespread access to the treatment, 
about 10,000 people perform at-home FMT in the 
United States each year, notwithstanding the infection 
risk associated with sharing stool.
As physicians have started to provide FMT to 
patients with recurrent CDI, stool banks have opened 
to provide fecal material to physicians performing 
FMT.  While there are a number of stool banks in 
hospitals, larger stool banks have opened, including 
OpenBiome in Cambridge, MA and Advancing Bio 
in California, that provide screened frozen fecal 
material ready for clinical use.  In addition, various 
applications of microbiome-based products to treat 
CDI and other conditions are currently being studied 
by pharmaceutical companies and biotechnology start-
ups, such as Seres Health, Rebiotix, and Repoopulate, 
that are developing specially-designed biotherapeutic 
products that treat CDI and other conditions by 
transferring microbial communities or cocktails to 
a recipient via enema, colonoscopy or orally in pill 
form. 
The Food and Drug Administration (FDA) is 
actively considering how to regulate FMT.  At present, 
FDA classifies FMT as a procedure involving live 
biotherapeutics (a category of drugs), but is exercising 
“enforcement discretion” for recurrent CDI if the 
donor is known to the recipient and if adequate 
informed consent is obtained from the patient.  On 
March 1, 2016, FDA issued another draft guidance 
document on FMT which does not alter FDA’s current 
enforcement discretion policy.  While the March 
2016 draft guidance does not include the requirement 
that the donor be known to the recipient, it states that 
FMT may be used for recurrent CDI if “the FMT 
product is not obtained from a stool bank.”  The draft 
guidance explicitly states that stool banks must have 
an IND application in place before distributing FMT 
product but – importantly – under the new guidance 
an IND sponsor may request a waiver of certain IND 
regulations when it is providing FMT product to 
doctors treating patients with recurrent CDI.   FDA 
is using the new March 2016 guidance to solicit 
feedback on this general proposal, and on which 
parts of the IND application would be appropriate to 
waive.
Under the grant, the co-investigators put together 
a working group of approximately 30 expert 
stakeholders including scientists, clinicians, patient 
and professional association advocates, bioethicists, 
academics, lawyers, and individuals from the 
biotechnology industries who have an interest in 
microbiota transplantation or expertise relevant to the 
project.  In addition, representatives of FDA and NIH 
participate as observers.  
At the first meeting in December, prominent 
microbiome researchers who are part of the working 
group discussed the microbiota communities that 
reside in the gut, vagina, nasal and oral cavities, 
and skin and the status and gaps in research about 
microbiota transplantation in those body sites.  The 
working group also studied potential frameworks for 
regulation of FMT including the existing frameworks 
for blood and tissue.  At the May meeting, the working 
group went beyond regulation of FMT and considered 
how vaginal and oral microbiota transplantation 
should be regulated by comparing the critical 
similarities and differences raised by transferring 
these microbial communities at different body sites.  
For instance, studies show that increased microbial 
diversity in the gut confers a health benefit, whereas 
a healthy vaginal tract is associated with colonization 
by a single Lactobacillus bacteria.  The working 
group considered this and other differences that 
might influence how different forms of MT should be 
regulated. 
At the May meeting, Dr. Rob Knight, a prominent 
microbiome researcher at University of California 
San Diego spoke to the working group via Skype 
regarding cutting edge research conducted by principal 
researcher Dr. Maria Dominguez-Bello, a New York 
University School of Medicine faculty member.  In 
what some call a “whole body microbiome transplant” 
researchers swabbed babies born by Cesarean section 
with gauze covered in their mothers' vaginal fluids.  
The concept is to confer the microbial communities 
the baby would have received if it had been born via 
the birth canal.  The transfer of maternal microbial 
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•	 Diane Hoffmann, Law & Health Care Program, University of Maryland Carey School of Law 
(Principal Investigator)
•	 Dr. Frank Palumbo, Center on Drugs and Public Policy, University of Maryland School of Pharmacy 
•	 Dr. Jacques Ravel, Institute for Genome Sciences, University of  Maryland School of Medicine
•	 Dr. Mary-Claire Roghmann, Department of Epidemiology and Public Health, University of 
Maryland School of Medicine 
•	 Dr. Erik von Rosenvinge, Division of Gastroenterology, University of Maryland School of Medicine 
and Veterans Affairs Maryland Health Care System 
•	 Virginia Rowthorn, Law & Health Care Program, University of Maryland Carey School of Law
UMB Microbiota Transplantation Investigators
communities is thought to help babies’ immune 
systems develop.  Only a small proof-of-concept study 
has been conducted to date, but there is excitement 
about this form of MT and the working group will 
consider how it should be regulated along with other 
forms of MT.  Dr. Knight also discussed the potential 
use of MT to treat malnourished infants whose gut 
microbiota may not be able to recover from the effects 
of malnutrition, thus leading to long-term negative 
health sequelae.
The working group will meet for the third and final 
time in December 2016 to finalize recommendations 
that will appear in a white paper.   
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On April 12, 2015, Freddie Carlos Gray, Jr., a 
25-year-old African American was arrested by 
the Baltimore Police Department for possessing a 
switchblade. While being transported in a police 
van, Gray fell into a coma and died from injuries 
to his spinal cord.  Mr. Gray was not secured inside 
the van while driving to the police station. On May 
1, 2015, the Baltimore City State's Attorney filed 
charges against six police officers after the medical 
examiner’s report ruled Gray's death a homicide on 
the grounds that Gray had died as a result of a 'rough 
ride'—a form of police brutality in which a victim 
is helplessly thrown around the interior of a police 
vehicle by deliberately abrupt police driving.  The 
incident caused demonstrations in Baltimore primarily 
among African Americans who wanted to express 
their anguish about the specific incident and decades 
of inequitable treatment on a multitude of fronts.  In 
response to the palpable distress of the city in the 
aftermath of the incident, eleven Maryland Carey 
Law faculty members, including Law & Health Care 
Program faculty members Michael Greenberger 
(course master), Diane Hoffmann, and Deborah 
Weimer, developed an 8-week course called Freddie 
Gray’s Baltimore: Past, Present and Moving Forward 
to help students at the University of Maryland Schools 
of Law and Social Work explore the causes of, and 
possible solutions to, the unrest in Baltimore.
The course attracted almost 100 law and social work 
students as well as extensive media coverage when 
it was introduced in Fall 2015.  The class was held 
in the law school’s largest lecture hall and its leaders 
still needed to turn away applicants. The course was 
offered again in Spring 2016 at the law school as 
well as to undergraduate students at the University of 
Maryland in College Park.  
The course focused on social, economic and other 
issues facing the citizens of Baltimore, including 
policing practices, criminal justice, access to housing, 
health care, education, joblessness and community 
development.  Professor Hoffmann organized the class 
module that discussed the intersection of poverty and 
health and worked with health law faculty members 
Deborah Weimer, Ellen Weber and Sara Gold to 
create a class that explained the impact of the social 
determinants of health (including socioeconomic 
status, education, the physical environment, 
employment, and social support networks) in 
Baltimore.  During the fall class, Dr. Leana S. Wen, 
the City of Baltimore’s Health Commissioner, 
spoke to the class about her efforts to improve the 
health of Baltimore’s residents which she sees as a 
critical cornerstone of well-being and social justice.  
Following Dr. Wen’s talk, the faculty team arranged 
for a “standardized patient” to interact with students.  
The “patient” was an actor taking on the role of a 
resident of the Sandtown Winchester neighborhood of 
Baltimore which suffers from a high level of poverty 
and need and was the home of Freddie Gray.  Students 
interacted with the patient regarding her health care 
needs and were able, through the stories she related, 
to understand the impact of her life’s challenges on 
her health and her ability to access health care.  After 
hearing from the patient, the students were asked 
how they as lawyers or social workers could help 
the patient in ways that might affect her health. The 
takeaway message for the students was that the law 
itself can be a social determinant of health. 
The Freddie Gray course arose from conversations 
among law school faculty about how to help students 
understand the many issues raised by Freddie Gray’s 
death.  The course is intended to be a springboard for 
further student and faculty involvement in citizen and 
government efforts to reform law and policy for the 
benefit of the city and beyond. 
“Freddie Gray’s Baltimore” – a New Course Designed to 
Teach and Heal
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Law & HeaLtH Care Program
500 West Baltimore Street
Baltimore, MD 21201
www.law.umaryland.edu/healthlaw
Comments and letters should be 
forwarded to the above address.
Support the Law & Health Care Program
The Law & Health Care Program has hosted a number of hallmark meetings and roundtables to bring 
together health care practitioners, legal academics, medical experts, scientists, and policymakers to 
examine cutting-edge issues in health policy, law, or ethics. Over the next 30 years, we hope to count you 
as a partner in this effort. We plan to build on the stellar foundation we have created as health law educators 
to keep asking questions and pushing the field of health law forward. In order to do this, we are asking for 
your support. Every contribution helps our program achieve its goals.
There are two ways to give to the Law & Health Care Program:
~ Online at http://www.law.umaryland.edu/give/healthlaw 
~ Mail, by sending a check made payable to: UMBF, Inc./ Law & Health Care 
to 620 West Lexington Street, 2nd Floor, Baltimore, MD 21201
Funds for the Law & Health Care Program are administered by the University of Maryland, Baltimore Foundation, Inc.
